Home LiteratureArticle Details
PMID: 32947928 Published · epublish English Journal Article

B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors.

Cancers ·Vol. 12 ·No. 9 ·2020-09-16

Tang J, Ramis-Cabrer D, Curull V, Wang X, Mateu-Jiménez M, Pijuan L, Duran X, Qin L, Rodríguez-Fuster A, Aguiló R, Barreiro E

Abstract

Immune profile of B and T cells and tertiary lymphoid structures (TLSs) may differ in tumors of lung cancer (LC) patients with/without chronic obstructive pulmonary disease (COPD), and may also influence patient survival. We sought to analyze: (1) TLSs, germinal centers (GCs), B and T cells, and (2) associations of the immune biomarkers with the patients' 10-year overall survival (OS). TLSs (numbers and area), B [cluster of differentiation (CD) 20], and T (CD3), and GCs cells were identified in both tumor and non-tumor specimens (thoracotomy) from 90 LC-COPD patients and 43 LC-only patients. Ten-year OS was analyzed in the patients. Immune profile in tumors of LC-COPD versus LC: TLS numbers and areas significantly decreased in tumors of LC-COPD compared to LC patients. No significant differences were observed in tumors between LC-COPD and LC patients for B or T cells. Immune profile in tumors versus non-tumor specimens: TLS areas and B cells significantly increased, T cells significantly decreased in tumors of both LC and LC-COPD patients. Survival: in LC-COPD patients: greater area of TLSs and proportion of B cells were associated with longer survival rates. The immune tumor microenvironment differs in patients with underlying COPD and these different phenotypes may eventually impact the response to immunotherapy in patients with LC.

Keywords
B cells chronic respiratory diseases lung cancer overall survival tertiary lymphoid structures
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Tang Jun
Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Medical School, Universitat Autònoma de Barcelona, Parc de Recerca Biomèdica de Barcelona (PRBB), 08003 Barcelona, Spain. | Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.
Ramis-Cabrer Daniel ORCID
Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Medical School, Universitat Autònoma de Barcelona, Parc de Recerca Biomèdica de Barcelona (PRBB), 08003 Barcelona, Spain.
Curull Víctor
Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Medical School, Universitat Autònoma de Barcelona, Parc de Recerca Biomèdica de Barcelona (PRBB), 08003 Barcelona, Spain. | Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.
Wang Xuejie
Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Medical School, Universitat Autònoma de Barcelona, Parc de Recerca Biomèdica de Barcelona (PRBB), 08003 Barcelona, Spain.
Mateu-Jiménez Mercé
Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Medical School, Universitat Autònoma de Barcelona, Parc de Recerca Biomèdica de Barcelona (PRBB), 08003 Barcelona, Spain.
Pijuan Lara ORCID
Pathology Department, Hospital del Mar-IMIM, Parc de Salut Mar, 08003 Barcelona, Spain.
Duran Xavier
Scientific, Statistics, and Technical Department, Hospital del Mar-IMIM, Parc de Salut Mar, 08003 Barcelona, Spain.
Qin Liyun
Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Medical School, Universitat Autònoma de Barcelona, Parc de Recerca Biomèdica de Barcelona (PRBB), 08003 Barcelona, Spain.
Rodríguez-Fuster Alberto
Thoracic Surgery Department, Hospital del Mar-IMIM, Parc de Salut Mar, 08003 Barcelona, Spain.
Aguiló Rafael
Thoracic Surgery Department, Hospital del Mar-IMIM, Parc de Salut Mar, 08003 Barcelona, Spain.
Barreiro Esther
Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Medical School, Universitat Autònoma de Barcelona, Parc de Recerca Biomèdica de Barcelona (PRBB), 08003 Barcelona, Spain. | Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.
References (50)
50 references, click to expand
  1. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.
    J Clin Oncol. 2008 Sep 20;26(27):4410-7 PMID: 18802153
  2. Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017).
    Arch Bronconeumol. 2018 Nov;54(11):568-575 PMID: 30241689
  3. Tertiary lymphoid structures in cancer and beyond.
    Trends Immunol. 2014 Nov;35(11):571-80 PMID: 25443495
  4. MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial.
    BMC Surg. 2018 May 18;18(1):27 PMID: 29776444
  5. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.
    PLoS One. 2012;7(12):e51862 PMID: 23251644
  6. The nature of small-airway obstruction in chronic obstructive pulmonary disease.
    N Engl J Med. 2004 Jun 24;350(26):2645-53 PMID: 15215480
  7. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.
    Arch Bronconeumol. 2017 Mar;53(3):128-149 PMID: 28274597
  8. Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer.
    Crit Rev Oncol Hematol. 2006 Sep;59(3):218-25 PMID: 16829124
  9. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
    Nature. 2020 Jan;577(7791):561-565 PMID: 31942071
  10. An Official American Thoracic Society Research Statement: A Research Framework for Pulmonary Nodule Evaluation and Management.
    Am J Respir Crit Care Med. 2015 Aug 15;192(4):500-14 PMID: 26278796
  11. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.
    Nat Med. 2004 Sep;10(9):927-34 PMID: 15311275
  12. Immunotherapy with Monoclonal Antibodies in Lung Cancer of Mice: Oxidative Stress and Other Biological Events.
    Cancers (Basel). 2019 Sep 04;11(9): PMID: 31487876
  13. The immune microenvironment: a major player in human cancers.
    Int Arch Allergy Immunol. 2014;164(1):13-26 PMID: 24852691
  14. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
    Nat Cell Biol. 2015 Jun;17(6):804-15 PMID: 26005835
  15. Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology.
    Curr Pharm Des. 2016;22(34):5300-5310 PMID: 27339432
  16. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery.
    Thorax. 2001 Feb;56(2):89-108 PMID: 11209097
  17. Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies.
    Respirology. 2016 Feb;21(2):269-79 PMID: 26567533
  18. Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment.
    Virus Genes. 2006 Oct;33(2):253-64 PMID: 16972041
  19. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
    Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940 PMID: 29518341
  20. B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease.
    Am J Respir Crit Care Med. 2015 Sep 15;192(6):695-705 PMID: 26073875
  21. Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice.
    J Cell Physiol. 2019 Aug;234(10):18041-18052 PMID: 30851071
  22. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.
    Arch Bronconeumol. 2017 Jun;53(6):324-335 PMID: 28477954
  23. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
    Chest. 2013 May;143(5 Suppl):e369S-e399S PMID: 23649447
  24. B cells and tertiary lymphoid structures promote immunotherapy response.
    Nature. 2020 Jan;577(7791):549-555 PMID: 31942075
  25. Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD.
    Cancers (Basel). 2020 May 13;12(5): PMID: 32414037
  26. Estimation of the Risk of Lung Cancer in Women Participating in a Population-Based Breast Cancer Screening Program.
    Arch Bronconeumol. 2020 May;56(5):277-281 PMID: 31629546
  27. B cells are associated with survival and immunotherapy response in sarcoma.
    Nature. 2020 Jan;577(7791):556-560 PMID: 31942077
  28. Cigarette smoke-induced emphysema: A role for the B cell?
    Am J Respir Crit Care Med. 2006 Apr 1;173(7):751-8 PMID: 16399994
  29. Chronic inflammation and cytokines in the tumor microenvironment.
    J Immunol Res. 2014;2014:149185 PMID: 24901008
  30. Screening in Lung Cancer: The Latest Evidence.
    Arch Bronconeumol. 2020 Jan;56(1):7-8 PMID: 31204006
  31. Clinical Characteristics and Risk of Exacerbations Associated With Different Diagnostic Criteria of Asthma-COPD Overlap.
    Arch Bronconeumol. 2020 May;56(5):282-290 PMID: 31784349
  32. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection.
    Chest. 2014 Feb;145(2):346-353 PMID: 24008835
  33. Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer.
    Oncol Lett. 2014 Oct;8(4):1682-1686 PMID: 25202391
  34. Cancer statistics, 2019.
    CA Cancer J Clin. 2019 Jan;69(1):7-34 PMID: 30620402
  35. The Eighth Edition Lung Cancer Stage Classification.
    Chest. 2017 Jan;151(1):193-203 PMID: 27780786
  36. Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease.
    J Thorac Oncol. 2017 Feb;12(2):235-248 PMID: 27793775
  37. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
    Int J Cancer. 2010 Dec 15;127(12):2893-917 PMID: 21351269
  38. The camKK2/camKIV relay is an essential regulator of hepatic cancer.
    Hepatology. 2015 Aug;62(2):505-20 PMID: 25847065
  39. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2014 May;45(5):787-98 PMID: 24578407
  40. Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2013 Aug 1;188(3):343-55 PMID: 23742729
  41. Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States.
    Front Oncol. 2015 May 26;5:113 PMID: 26075181
  42. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
    Int J Chron Obstruct Pulmon Dis. 2019 May 01;14:929-938 PMID: 31118602
  43. Macrophages, Inflammation, and Lung Cancer.
    Am J Respir Crit Care Med. 2016 Jan 15;193(2):116-30 PMID: 26583808
  44. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.
    Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44 PMID: 24484236
  45. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice.
    J Immunol. 2006 Oct 1;177(7):4350-9 PMID: 16982869
  46. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.
    Lancet. 2004 Aug 21-27;364(9435):709-21 PMID: 15325838
  47. Reduced tumor burden through increased oxidative stress in lung adenocarcinoma cells of PARP-1 and PARP-2 knockout mice.
    Biochimie. 2016 Feb;121:278-86 PMID: 26700152
  48. The effect of different comorbidities on survival of non-small cells lung cancer patients.
    Lung. 2015 Apr;193(2):291-7 PMID: 25516286
  49. The Declaration of Helsinki on Medical Research involving Human Subjects: A Review of Seventh Revision.
    J Nepal Health Res Counc. 2020 Jan 21;17(4):548-552 PMID: 32001865
  50. Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
    Am J Respir Crit Care Med. 2018 Feb 1;197(3):325-336 PMID: 28934595
Full Text / Full Text
PMC full text available locally, click to read

Loading full text...

Article Info
Journal
Cancers
Abbr.
Cancers (Basel)
ISSN
2072-6694
DOI
10.3390/cancers12092644
Published
2020-09-16
Epub
2020-00-16
Language
English
Region
Switzerland
NLM ID
101526829
PMCID
PMC7564217
Grants
Instituto de Salud Carlos III · FIS18/00075
Instituto de Salud Carlos III · CIBERES 2019
Sociedad Española de Neumología y Cirugía Torácica · SEPAR 2018
Sociedad Española de Neumología y Cirugía Torácica · SEPAR 2020
Menarini SA · Menarini SA 2018
External Links
PubMed source DOI: 10.3390/cancers12092644 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2